Subtype
Cholangiocarcinoma
CI-CAN-00004932CCExplore in graph →
210 active trials3 approved drugs29 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00004932CCExplore in graph →
Clinical trials
760 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (106)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03278106 | TAS-102 in Treating Advanced Biliary Tract Cancers | completed | Phase 2 | 28 | Mayo ClinicOTHER | 1 | Jun 28, 2023 | clinicaltrials |
| NCT05913661 | Pemigatinib Combined With PD-1 Inhibitor in Unresectable or Metastatic Intrahepatic Cholangiocarcinoma | unknown | Phase 2 | 30 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Jun 22, 2023 | clinicaltrials |
| NCT04440943 |
| A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies |
| completed |
| Phase 1 |
| 27 |
| Celldex TherapeuticsINDUSTRY |
| 1 |
| Jun 18, 2023 |
| clinicaltrials |
| NCT00301379 | Registry Study of Neoadjuvant Chemoradiation & Transplant for Cholangiocarcinoma Patients | terminated | — | 59 | Washington University School of MedicineOTHER | 1 | Jun 15, 2023 | clinicaltrials |
| NCT02520141 | Ramucirumab in Treating Patients With Advanced or Metastatic, Previously Treated Biliary Cancers That Cannot Be Removed by Surgery | completed | Phase 2 | 61 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 15, 2023 | clinicaltrials |
| NCT03473574 | Durvalumab and Tremelimumab With Gemcitabine or Gemcitabine/Cisplatin Compared to Gemcitabine/Cisplatin in CCA Patients(IMMUCHEC) | completed | Phase 2 | 128 | AIO-Studien-gGmbHOTHER | 1 | Jun 15, 2023 | clinicaltrials |
| NCT05896956 | The Construction of Clinical Database and Multiomics Biobank Based on a Multicentral Prospective Cohort of Benign and Malignant Biliary Tract Diseases | not yet recruiting | — | 500 | RenJi HospitalOTHER | 0 | Jun 9, 2023 | clinicaltrials |
| NCT02333188 | Genetic Analysis-Guided Dosing of FOLFIRABRAX in Treating Patients With Advanced Gastrointestinal Cancer | completed | Phase 1 | 50 | University of ChicagoOTHER | 1 | May 31, 2023 | clinicaltrials |
| NCT03820310 | Clinical Trial of Autologous Tcm Immunotherapy in ICC | unknown | Phase 2 | 20 | Newish Technology (Beijing) Co., Ltd.INDUSTRY | 1 | May 24, 2023 | clinicaltrials |
| NCT02351765 | ABC-08: Phase Ib Trial of Acelarin in Combination With Cisplatin in Locally Advanced/ Metastatic Biliary Tract Cancers(ABC-08) | completed | Phase 1 | 21 | The Christie NHS Foundation TrustOTHER | 1 | May 17, 2023 | clinicaltrials |
| NCT02174575 | Anesthetic Agents and Acute Kidney Injury After Liver Resection Surgery | withdrawn | Phase 4 | 0 | Tokyo Medical and Dental UniversityOTHER | 1 | May 3, 2023 | clinicaltrials |
| NCT04454905 | Camrelizumab in Combination With Apatinib in Advanced ICC: A Single-arm Phase II Study | unknown | Phase 2 | 50 | Sun Yat-sen UniversityOTHER | 1 | Apr 19, 2023 | clinicaltrials |
| NCT05400902 | HAIC Combined With Sintilimab and Bevacizumab for Unresectable Intrahepatic Cholangiocarcinoma | unknown | Phase 2 | 17 | Binkui LiOTHER | 1 | Apr 13, 2023 | clinicaltrials |
| NCT04556214 | Liver Transplantation for Non-Resectable Intrahepatic Cholangiocarcinoma: a Prospective Exploratory Trial (TESLA Trial) | recruiting | N/A | 15 | Oslo University HospitalOTHER | 1 | Apr 11, 2023 | clinicaltrials |
| NCT05805956 | IMM2902 in Patients With Advanced Solid Tumors Expressing HER2 | unknown | Phase 1 / Phase 2 | 105 | ImmuneOnco Biopharmaceuticals (Shanghai) Inc.OTHER | 1 | Apr 10, 2023 | clinicaltrials |
| NCT03849469 | A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors(DUET-4) | completed | Phase 1 | 78 | Xencor, Inc.INDUSTRY | 1 | Mar 30, 2023 | clinicaltrials |
| NCT03895970 | Lenvatinib Combined Pembrolizumab in Advanced Hepatobiliary Tumors | completed | Phase 2 | 32 | Peking Union Medical College HospitalOTHER | 1 | Mar 29, 2023 | clinicaltrials |
| NCT02821754 | A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC) | completed | Phase 2 | 54 | National Cancer Institute (NCI)NIH | 1 | Mar 28, 2023 | clinicaltrials |
| NCT03801915 | Perioperative MVT-5873, a Fully Human Monoclonal Antibody Against a CA 19-9 Epitope, for Operable CA 19-9 Producing Pancreatic Cancers, Cholangiocarcinomas, and Metastatic Colorectal Cancers | completed | Phase 2 | 10 | National Cancer Institute (NCI)NIH | 1 | Mar 21, 2023 | clinicaltrials |
| NCT04565275 | A Study of ICP-192 in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 45 | Beijing InnoCare Pharma Tech Co., Ltd.INDUSTRY | 2 | Mar 14, 2023 | clinicaltrials |
| NCT05374122 | AI Guidance for Biopsy in Suspected Cholangiocarcinoma | unknown | N/A | 48 | Instituto Ecuatoriano de Enfermedades DigestivasOTHER | 1 | Mar 6, 2023 | clinicaltrials |
| NCT05694845 | Evaluation of the Patient's Experience in Medical Studies for Cholangiocarcinoma | unknown | — | 500 | Power Life Sciences Inc.INDUSTRY | 0 | Mar 6, 2023 | clinicaltrials |
| NCT05028439 | RFA Combined With Chemotherapy for Unresectable Cholangiocarcinoma | completed | N/A | 70 | First People's Hospital of HangzhouOTHER | 1 | Feb 21, 2023 | clinicaltrials |
| NCT05519319 | Safety and Efficacy of PDT vs RFA vs PDT+RFA for the Treatment of Extrahepatic Cholangiocarcinoma | unknown | N/A | 70 | First People's Hospital of HangzhouOTHER | 1 | Feb 21, 2023 | clinicaltrials |
| NCT05721963 | Study on the Accuracy of Proteomics in Evaluating Lymph Node Metastasis Status in Cholangiocarcinoma Patients | unknown | — | 30 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Feb 10, 2023 | clinicaltrials |
| NCT05718349 | FGF19 in Obstructive Cholestasis: "Unveil the Signal"(FOCUS) | unknown | — | 81 | Nicole HildebrandOTHER | 1 | Feb 8, 2023 | clinicaltrials |
| NCT04077372 | Assessment of a Serious Illness Conversation Guide (SICG) in Advanced Gastro-Intestinal Cancers | terminated | N/A | 12 | Stanford UniversityOTHER | 1 | Jan 27, 2023 | clinicaltrials |
| NCT05697237 | Carlizumab Plus Sovantinib in Second-line Treatment of Advanced or Metastatic Cholangiocarcinoma | unknown | N/A | 60 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 0 | Jan 25, 2023 | clinicaltrials |
| NCT04430842 | Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S | completed | Phase 1 | 15 | Quadriga Biosciences, Inc.INDUSTRY | 1 | Jan 18, 2023 | clinicaltrials |
| NCT02393248 | Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101) | terminated | Phase 1 / Phase 2 | 201 | Incyte CorporationINDUSTRY | 2 | Jan 6, 2023 | clinicaltrials |
| NCT05672537 | Durvalumab Combined With GemCis Neoadjuvant Therapy of Resectable Intrahepatic Cholangiocarcinoma With High Recurrence Risk | unknown | Phase 2 | 70 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jan 5, 2023 | clinicaltrials |
| NCT05653817 | Advanced or Metastatic Cholangiocarcinoma | unknown | N/A | 60 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 0 | Dec 16, 2022 | clinicaltrials |
| NCT00286013 | Feasibility of Radiotherapy and Concomitant Gemcitabine and Oxaliplatin in Locally Advanced Pancreatic Cancer and Distal Cholangiocarcinoma | completed | Phase 2 | 24 | University Hospital, GhentOTHER | 1 | Dec 9, 2022 | clinicaltrials |
| NCT05644743 | Clinical Transformation of Organoid Model to Predict the Efficacy of GC in the Treatment of Intrahepatic Cholangiocarcinoma | not yet recruiting | — | 40 | Chengjun Sui,MDOTHER | 0 | Dec 9, 2022 | clinicaltrials |
| NCT05641233 | Preoperative Radiotherapy in Patients at High Risk of Postoperative Pancreatic Fistula After Pancreatoduodenectomy(FIBROPANC-1) | unknown | Phase 1 / Phase 2 | 33 | Erasmus Medical CenterOTHER | 1 | Dec 7, 2022 | clinicaltrials |
| NCT03079427 | Adjuvant Capecitabine vs Gemcitabine Plus Cisplatin in Resected Extrahepatic Cholangiocarcinoma | completed | Phase 2 | 101 | Asan Medical CenterOTHER | 1 | Dec 6, 2022 | clinicaltrials |
| NCT05634694 | Study on Consistency Evaluation for Drug Sensitivity of Patient-Derived Organoid Model From Cholangiocarcinoma Patients | unknown | — | 40 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Dec 2, 2022 | clinicaltrials |
| NCT03517488 | A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors(DUET-2) | completed | Phase 1 | 150 | Xencor, Inc.INDUSTRY | 1 | Dec 1, 2022 | clinicaltrials |
| NCT04076761 | Study of TRIFLURIDINE/TIPIRACIL in Previously Treated Cholangiocarcinoma(MOCHA) | terminated | Phase 2 | 8 | Sunnybrook Health Sciences CentreOTHER | 1 | Dec 1, 2022 | clinicaltrials |
| NCT05626127 | MRI-based Clinico-radiomics Predicting Lymph Node Metastasis Status of Hilar Cholangiocarcinoma | unknown | — | 60 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Nov 23, 2022 | clinicaltrials |
| NCT04304781 | Phase 1 In-vivo Biliary Study of KSP/QRH Heptapeptide Dimer | terminated | Phase 1 | 12 | Danielle Kim TurgeonOTHER | 1 | Nov 22, 2022 | clinicaltrials |
| NCT05580328 | An Exploratory Clinical Study of Photodynamic Therapy Combined With Sonodynamic Therapy in Cholangiocarcinoma | unknown | N/A | 10 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 0 | Nov 14, 2022 | clinicaltrials |
| NCT04078230 | Regional or Extend LymphAdenectomy During Resection of Intrahepatic Cholangiocarcinoma | recruiting | N/A | 168 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 2 | Nov 9, 2022 | clinicaltrials |
| NCT05596370 | Association Between Cell-free Nucleic Acid in Blood, Urine and Microbiome in Stool With Pancreatobiliary Cancer | unknown | — | 150 | Seoul National University HospitalOTHER | 1 | Nov 7, 2022 | clinicaltrials |
| NCT02773485 | Chemo Alone or in Combination With Radiation in Unresectable Cholangiocarcinoma | unknown | Phase 3 | 155 | Tata Memorial HospitalOTHER_GOV | 1 | Oct 21, 2022 | clinicaltrials |
| NCT02415036 | Melphalan for Use With the Hepatic Delivery System Treatment in Patients With Unresectable Hepatocellular Carcinoma or Intra Hepatic Cholangiocarcinoma | terminated | Phase 2 | 17 | Delcath Systems Inc.INDUSTRY | 1 | Oct 17, 2022 | clinicaltrials |
| NCT04801095 | A Phase I Study of WM-S1-030 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 100 | Wellmarker BioINDUSTRY | 2 | Sep 16, 2022 | clinicaltrials |
| NCT03769753 | Trial of IRE in Cholangiocarcinoma | completed | Phase 2 | 8 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 10, 2022 | clinicaltrials |
| NCT05535647 | Second Line Therapy for Advanced Intrahepatic Cholangiocarcinoma | unknown | Phase 2 | 60 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Sep 10, 2022 | clinicaltrials |
| NCT03353181 | Application of Endoscopic Scissors Cutting ENBD Tube in the Treatment of Malignant Hilar Biliary Strictures(ENBD) | withdrawn | N/A | 0 | Changhai HospitalOTHER | 1 | Aug 25, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Jun 28, 2023source: clinicaltrials